Vaccines for Enteric Diseases

6-8 November 2013, The Royal Orchid Sheraton Hotel & Towers, Bangkok, Thailand

  • Increase font size
  • Default font size
  • Decrease font size


Vaccines For Enteric Diseases (VED 2013), will address the diverse aspects of vaccines to counter human enteric diseases. With regard to global public health issues, enteric diseases probably represent the first cause of infectious morbidity and second cause of infectious mortality worldwide. The added complications surrounding the increasing resistance to bacterial enteric pathogens to antibiotics are creating a worldwide trend that will require enhanced enteric vaccine strategies. Taking into consideration the major difficulties faced in drastically improving the sanitary conditions in large areas of the developing world which accounts for more than 95% of enteric infections, enteric vaccine strategies may become the prime preventative approach. Enteric infections also present problems in the industrialized world where the food chain continues to be compromised by enteric pathogens.

Believe in Thailand

Scientific Advisory Panel

Duncan Steele (Bill & Melinda Gates Foundation, USA)
Timo Vesikari (University of Tampere, Finland)
Carol O. Tacket (University of Maryland, USA)
Mary Estes (Baylor College of Medicine, USA)
Myron M. Levine (University of Maryland, USA)
John D. Clemens (ICDDR, Dhaka, Bangladesh)
Kevin Killeen (Matrivax Corporation, Boston, USA)
Ann-Mari Svennerholm (Göteborg University, Sweden)
Margaret E. Conner (Baylor College of Medicine, USA)
Linda J. Saif (Ohio State University, USA)
Roger I. Glass (Fogarty Center, NIH, Bethesda, USA)
Harry B. Greenberg (Stanford University, USA)
Claire-Lise Chaignat (WHO, Switzerland)
John D. Clements (Tulane University, USA)
Umesh Parashar (CDC, Atlanta, USA)
Julie E. Bines (Royal Children’s Hospital, Melbourne, Australia)
Thomas G. Brewer (Bill & Melinda Gates Foundation, USA)
Mark Riddle (NMRC, Bethesda, Maryland, USA)
Armelle Phalipon (Pasteur Institute, Paris, France)
Lou Bourgeois (PATH, Washington DC, USA)
Robert Hall (NIAID/NIH, Bethesda, Maryland, USA)
Sathit Pitchayangkul (AFRIMS, Bangkok, Thailand)
Serge Debrus (GSK Biologicals, Wavre, Belgium)
Ladaporn Bodhidatta (AFRIMS, Bangkok, Thailand)
Punnee Pittisutithum (Madihol University, Bangkok, Thailand)
Carl J. Mason (AFRIMS, Bangkok, Thailand)
Bernd Benninghoff (GSK Biologicals, Wavre, Belgium)

VED 2013 will focus on:

  • Epidemiology
  • Virology
  • Microbiology
  • Immunology
  • Mechanisms of Pathophysiology
  • Immune Responses to Enteric Pathogens
  • New Vaccine Vectors
  • Enteric Vaccine Adjuvants
  • Animal Models Studies
  • Animal Disease
  • Vaccine Delivery Systems
  • Enteric Vaccine Field Testing
  • Salmonella Typhi and Live Vectors
  • Shigella
  • Cholera
  • Escherchia Coli (enterotoxigenic)
  • Rotavirus (Rotarix® vaccine and RotaTeq® vaccine)
  • Live versus Killed Vaccines
  • Etec
  • Campylobacter
  • Heliobacter Pylori
  • Chlostridium Difficile
  • Entamoeba Histolytica
  • Protazoa
  • Viral Vaccines (Human Caliciviruses, Rotavirus, Norwalk-like viruses, Coronaviruses, Adenovirus, Astrovirus)
  • Mucosal Immunization
  • DNA Vaccines
  • Edible Plant Vaccines
  • Transcutaneous Vaccines
  • Food Safety Vaccines
  • Vaccine Production Issues
  • Enteric Vaccine Construction and Design
  • DNA Delivery of Transgenes by Enteric Vaccines
  • Problems with and usage of enteric vaccines in developing countries
  • Specific treatments against acute diarrhea
  • New Developments and Initiatives with enteric vaccines

VED 2013 will be a major opportunity to:

  • Re-evaluate the diarrheal disease burden both in the industrialized and developing worlds
  • Discuss which diseases, depending on the area, would require an immunization strategy and if eradication or control of the selected disease is achievable by a vaccine
  • Discuss the state-of-the-art vaccine candidates currently available
  • Discuss obstacles to obtaining institutional and industrial support for these vaccines
  • Review of studies in developing countries
  • Air views on the lack of facilities for enteric vaccine trials
  • Discuss the distribution of vaccines and implementation policy in the developing world

VED 2013 Delegates

Login details will be supplied after you have registered for the event.

VED 2013 Venue

VED 2013 Sponsors

  • Takeda
  • Matrivax
  • PATH
  • Sanofi Pasteur
  • UMN
  • BioVAXX
  • Aldevron
  • GlaxoSmithKline Biologicals
  • Crucell
  • Intercell
  • Retroscreen Virology
  • University of Tampere Vaccine Research Center
  • Novartis Vaccines
  • Mucosis
  • Aridis Pharmaceuticals
  • Nature Gene Therapy
  • Thailand Convention & Exhibition Burea
  • Reagensia

VED 2013 Downloads

VED 2013 Leaflet

VED 2013 Mailing List

E-mail Address
What is 1+4-2?